摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanone | 1161364-04-0

中文名称
——
中文别名
——
英文名称
1-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanone
英文别名
1-acetyl-3-tert-butyl-5-aminopyrazole;1-(5-Amino-3-tert-butylpyrazol-1-yl)ethanone
1-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanone化学式
CAS
1161364-04-0
化学式
C9H15N3O
mdl
——
分子量
181.238
InChiKey
HULAHZJCUAJHON-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    323.0±44.0 °C(Predicted)
  • 密度:
    1.13±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    60.9
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanoneammonium hydroxide三乙胺 作用下, 以 甲醇二氯甲烷二甲基亚砜 为溶剂, 反应 27.0h, 生成 1-(3-(tert-butyl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea
    参考文献:
    名称:
    COMBINATION OF POLYAROMATIC UREA DERIVATIVES AND GLUCOCORTICOID OR HDAC INHIBITOR FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH MUSCLE CELLS AND/OR SATELLITE CELLS
    摘要:
    本发明提供了一种与皮质类固醇或HDAC抑制剂联合使用的化合物,用于治疗、改善、延缓、治愈和/或预防与肌肉细胞和/或卫星细胞相关的疾病或病症,如杜氏肌萎缩症、贝克肌萎缩症、消瘦或肌肉萎缩症。
    公开号:
    EP4029501A1
  • 作为产物:
    描述:
    乙酸酐3-叔丁基-吡唑-5-胺4-二甲氨基吡啶三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 以41%的产率得到1-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanone
    参考文献:
    名称:
    COMBINATION OF POLYAROMATIC UREA DERIVATIVES AND GLUCOCORTICOID OR HDAC INHIBITOR FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH MUSCLE CELLS AND/OR SATELLITE CELLS
    摘要:
    本发明提供了一种与皮质类固醇或HDAC抑制剂联合使用的化合物,用于治疗、改善、延缓、治愈和/或预防与肌肉细胞和/或卫星细胞相关的疾病或病症,如杜氏肌萎缩症、贝克肌萎缩症、消瘦或肌肉萎缩症。
    公开号:
    EP4029501A1
点击查看最新优质反应信息

文献信息

  • [EN] POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES<br/>[FR] DÉRIVÉS D'URÉE POLYAROMATIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES MUSCULAIRES
    申请人:ANAGENESIS BIOTECHNOLOGIES S A S
    公开号:WO2021013712A1
    公开(公告)日:2021-01-28
    The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.
    当前的发明提供尿素生物,特别是具有核心结构杂环基-NH-CO-NH-芳基-O-杂环基的化合物,用于治疗、改善、延缓、治愈和/或预防与肌肉细胞和/或卫星细胞相关的疾病或症状,如杜兴氏肌肉萎缩症、贝克氏肌肉萎缩症、虚弱或肌肉萎缩症。
  • INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA
    申请人:Ammendola Aldo
    公开号:US20090192192A1
    公开(公告)日:2009-07-30
    The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.
    本发明涉及使用化合物作为广谱细菌生物膜形成的抑制剂。具体而言,本发明涉及一系列化合物,能够阻断革兰氏阴性和革兰氏阳性细菌的群体感应系统,一种制造它们的方法,含有它们的制药组合物以及它们用于治疗和预防细菌损害和疾病的用途,特别是对于需要抑制病原体的群体感应调节表型的疾病有优势的情况。
  • [EN] INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA<br/>[FR] INHIBITEURS DE LA FORMATION DE BIOFILMS DE BACTÉRIES GRAM POSITIF ET GRAM NÉGATIF
    申请人:QUONOVA LLC
    公开号:WO2009077844A2
    公开(公告)日:2009-06-25
    The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.
查看更多